X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow turns positive

Q1 FY2026 free cash flow was $0, compared with -$15.37M a year earlier. Trailing-twelve-month free cash flow was -$73.25M. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Free cash flow amounted to 252.4% of revenue in FY2025, down 5153.4 pp from a year earlier.
  • Free cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly free cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$18.31M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$88.62M-35.9% YoY
LTMMar 2026
-$73.25M-35.1% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-35.9%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(88.62M) USD
Year-over-year change
+35.9%

Free Cash Flow vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 free cash flow of $73.25M is the largest of the 4 companies compared; the peer median is $50.79M.
  • Its year-over-year change of -35.1% is the 2nd highest of 4, against a peer median of -36.5%.
  • Free cash flow amounts to 812.6% of revenue for XFOR, versus a peer median of 39.1%.
XFOR Competitors Peer median
Free Cash Flow for XFOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$73.25M -35.1%+4.7%812.6%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$59.11M -51.8%-20.4%39.1%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$50.79M -2.8%+22.7%—
INMBINmune Bio, Inc.LTM Mar 2026$20.78M -36.5%+1.4%—
Peer median (excluding XFOR) $50.79M-36.5%+1.4%39.1%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Depreciation & Amortization1.89M513K419K796K1.28M
Deferred Income Tax00000
Stock-Based Compensation05.2M8.69M8.2M4.3M
Change in Working Capital(1.5M)5.74M344K2.68M(2.58M)
Accounts Receivables000(1.07M)497K
Inventory000(2.82M)(1.66M)
Accounts Payables1.17M3.43M1.23M(286K)(2.98M)
Other Working Capital(2.66M)2.31M(890K)6.85M1.57M
Other Non-Cash Items17.4M5.32M(4.8M)(105.13M)(9.42M)
Operating Cash Flow(70.91M)(77.1M)(96.51M)(130.9M)(85.62M)
Capital Expenditures(615K)(103K)(60K)(7.33M)(3M)
Acquisitions (Net)00000
Purchases of Investments00(16.82M)(57.13M)(63.39M)
Sales of Investments002M26.45M74.54M
Other Investing Activities00098M0
Investing Cash Flow(615K)(103K)(14.88M)66.99M8.15M
Debt Repayment0(795K)20.44M20M0
Common Stock Issued76.25M122.63M60M294K238.53M
Common Stock Repurchased(2M)0000
Dividends Paid00000
Other Financing Activities0(4.61M)8.08M098K
Financing Cash Flow74.25M117.23M88.52M20.29M238.63M
Effect of Forex Changes90K(105K)99K(156K)213K
Net Change in Cash2.82M39.92M(22.78M)(43.77M)161.38M
Free Cash Flow(71.52M)(77.21M)(96.57M)(138.23M)(88.62M)

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.